14 April 2026 Zurich, Switzerland-based CRO InSphero, the global leader in 3D cell-based assays and organ-on-chip systems, announces the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early assessment of gastrointestinal (GI) liabilities in drug discovery. Despite efforts to flag GI toxicity risk early in the drug discovery process, DIGIT remains among the most common cau

20 May 2026 Zurich-based CRO InSphero, global leader in advanced 3D in vitro products and services, announces the acquisition of PhenoVista Biosciences to expand its high-content imaging and phenotypic analysis capabilities for drug discovery and safety testing. San Diego-based CRO PhenoVista Biosciences, Inc., is a leading provider in high-content imaging, cell painting, and functional cellular analysis for the biopharmaceutical industry. Their diverse repertoire includ